Teva Pharmaceutical Industries annual net income
2007
2008
2009
2010
2011
2012
2013
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Teva Pharmaceutical Industries Net Income Growth & History (TEVA)
Teva Pharmaceutical Industries's net income was $1.41B for fiscal 2025.
View full Teva Pharmaceutical Industries company overviewTeva Pharmaceutical Industries annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.41B | $3.05B | — |
| 2024 | 2024-12-31 | −$1.64B | −$1.08B | — |
| 2023 | 2023-12-31 | −$559.0M | $1.89B | — |
| 2022 | 2022-12-31 | −$2.45B | −$2.86B | — |
| 2021 | 2021-12-31 | $417.0M | $4.41B | — |
| 2020 | 2020-12-31 | −$3.99B | −$2.99B | — |
| 2019 | 2019-12-31 | −$999.0M | $1.15B | — |
| 2018 | 2018-12-31 | −$2.15B | $14.12B | — |
| 2017 | 2017-12-31 | −$16.27B | −$16.59B | — |
| 2016 | 2016-12-31 | $329.0M | — | — |
| 2013 | 2013-12-31 | $1.27B | −$694.0M | −35.35% |
| 2012 | 2012-12-31 | $1.96B | −$796.0M | −28.85% |
| 2011 | 2011-12-31 | $2.76B | −$572.0M | −17.17% |
| 2010 | 2010-12-31 | $3.33B | $1.33B | +66.55% |
| 2009 | 2009-12-31 | $2.00B | $1.39B | +228.41% |
| 2008 | 2008-12-31 | $609.0M | −$1.30B | −68.18% |
| 2007 | 2007-12-31 | $1.91B | — | — |
Teva Pharmaceutical Industries quarterly net income
Q1.08
Q2.08
Q3.08
Q4.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q1.16
Q2.16
Q3.16
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$576.0M | −$858.0M | — |
| Q1 2026 | 2026-03-31 | $369.0M | $155.0M | +72.43% |
| Q4 2025 | 2025-12-31 | $481.0M | $698.0M | — |
| Q3 2025 | 2025-09-30 | $433.0M | $870.0M | — |
| Q2 2025 | 2025-06-30 | $282.0M | $1.13B | — |
| Q1 2025 | 2025-03-31 | $214.0M | $353.0M | — |
| Q4 2024 | 2024-12-31 | −$217.0M | −$681.0M | — |
| Q3 2024 | 2024-09-30 | −$437.0M | −$506.0M | — |
| Q2 2024 | 2024-06-30 | −$846.0M | $26.0M | — |
| Q1 2024 | 2024-03-31 | −$139.0M | $81.0M | — |
| Q4 2023 | 2023-12-31 | $464.0M | $1.76B | — |
| Q3 2023 | 2023-09-30 | $69.0M | $8.0M | +13.11% |
| Q2 2023 | 2023-06-30 | −$872.0M | −$621.0M | — |
| Q1 2023 | 2023-03-31 | −$220.0M | $735.0M | — |
| Q4 2022 | 2022-12-31 | −$1.30B | −$1.14B | — |
| Q3 2022 | 2022-09-30 | $61.0M | −$231.0M | −79.11% |
| Q2 2022 | 2022-06-30 | −$251.0M | −$458.0M | — |
| Q1 2022 | 2022-03-31 | −$955.0M | −$1.03B | — |
| Q4 2021 | 2021-12-31 | −$159.0M | −$309.0M | — |
| Q3 2021 | 2021-09-30 | $292.0M | $4.64B | — |
| Q2 2021 | 2021-06-30 | $207.0M | $67.0M | +47.86% |
| Q1 2021 | 2021-03-31 | $77.0M | $8.0M | +11.59% |
| Q4 2020 | 2020-12-31 | $150.0M | $40.0M | +36.36% |
| Q3 2020 | 2020-09-30 | −$4.35B | −$4.04B | — |
| Q2 2020 | 2020-06-30 | $140.0M | $829.0M | — |
| Q1 2020 | 2020-03-31 | $69.0M | $174.0M | — |
| Q4 2019 | 2019-12-31 | $110.0M | $3.00B | — |
| Q3 2019 | 2019-09-30 | −$314.0M | −$106.0M | — |
| Q2 2019 | 2019-06-30 | −$689.0M | −$513.0M | — |
| Q1 2019 | 2019-03-31 | −$105.0M | −$1.23B | — |
| Q4 2018 | 2018-12-31 | −$2.89B | $8.65B | — |
| Q3 2018 | 2018-09-30 | −$208.0M | −$803.0M | — |
| Q2 2018 | 2018-06-30 | −$176.0M | $5.79B | — |
| Q1 2018 | 2018-03-31 | $1.12B | $475.0M | +73.64% |
| Q4 2017 | 2017-12-31 | −$11.54B | −$10.56B | — |
| Q3 2017 | 2017-09-30 | $595.0M | $183.0M | +44.42% |
| Q2 2017 | 2017-06-30 | −$5.97B | −$6.22B | — |
| Q1 2017 | 2017-03-31 | $645.0M | $9.0M | +1.42% |
| Q4 2016 | 2016-12-31 | −$973.0M | — | — |
| Q3 2016 · Sep 30 | 2016-09-30 | $412.0M | $309.0M | +300.00% |
| Q2 2016 · Jun 30 | 2016-06-30 | $254.0M | −$285.0M | −52.88% |
| Q1 2016 · Mar 31 | 2016-03-31 | $636.0M | $190.0M | +42.60% |
| Q3 2016 · Sep 30 | 2015-09-30 | $103.0M | −$773.0M | −88.24% |
| Q2 2016 · Jun 30 | 2015-06-30 | $539.0M | −$209.0M | −27.94% |
| Q1 2016 · Mar 31 | 2015-03-31 | $446.0M | −$298.0M | −40.05% |
| Q3 2014 | 2014-09-30 | $876.0M | $165.0M | +23.21% |
| Q2 2014 | 2014-06-30 | $748.0M | $1.20B | — |
| Q1 2014 | 2014-03-31 | $744.0M | $114.0M | +18.10% |
| Q4 2013 | 2013-12-31 | $380.0M | $60.0M | +18.75% |
| Q3 2013 | 2013-09-30 | $711.0M | $790.0M | — |
| Q2 2013 | 2013-06-30 | −$452.0M | −$1.31B | — |
| Q1 2013 | 2013-03-31 | $630.0M | −$229.0M | −26.66% |
| Q4 2012 | 2012-12-31 | $320.0M | −$186.0M | −36.76% |
| Q3 2012 | 2012-09-30 | −$79.0M | −$995.0M | — |
| Q2 2012 | 2012-06-30 | $863.0M | $287.0M | +49.83% |
| Q1 2012 | 2012-03-31 | $859.0M | $98.0M | +12.88% |
| Q4 2011 | 2011-12-31 | $506.0M | −$265.0M | −34.37% |
| Q3 2011 | 2011-09-30 | $916.0M | −$134.0M | −12.76% |
| Q2 2011 | 2011-06-30 | $576.0M | −$221.0M | −27.73% |
| Q1 2011 | 2011-03-31 | $761.0M | $48.0M | +6.73% |
| Q4 2010 | 2010-12-31 | $771.0M | $392.0M | +103.43% |
| Q3 2010 | 2010-09-30 | $1.05B | $401.0M | +61.79% |
| Q2 2010 | 2010-06-30 | $797.0M | $276.0M | +52.98% |
| Q1 2010 | 2010-03-31 | $713.0M | $262.0M | +58.09% |
| Q4 2009 | 2009-12-31 | $379.0M | $1.07B | — |
| Q3 2009 | 2009-09-30 | $649.0M | $18.0M | +2.85% |
| Q2 2009 | 2009-06-30 | $521.0M | −$12.0M | −2.25% |
| Q1 2009 | 2009-03-31 | $451.0M | $312.0M | +224.46% |
| Q4 2008 | 2008-12-31 | −$694.0M | — | — |
| Q3 2008 | 2008-09-30 | $631.0M | — | — |
| Q2 2008 | 2008-06-30 | $533.0M | — | — |
| Q1 2008 | 2008-03-31 | $139.0M | — | — |
Teva Pharmaceutical Industries net income trends
Over the last five fiscal years, Teva Pharmaceutical Industries's net income increased from −$3.99B to $1.41B, a change of $5.40B. The latest reported quarter, Q2 2026, shows −$576.0M.
About the metric
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
Calculation and source
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Teva Pharmaceutical Industries source filings ↗